Zusammenfassung
In der Erwachsenenmedizin liegen zahlreiche klinische Studien vor, die die Wirkung von Bisphosphonaten als effektive Hemmer der Knochenresorption eindeutig belegen [17], [19], [21], [35]. Bisphosphonate sind im Erwachsenenalter hauptsächlich zur Behandlung der Osteoporose oder der tumorassoziierten Hyperkalziämie indikationsabhängig zugelassen [18], [20], [21]. Der erfolgreiche Einsatz von Bisphosphonaten beim Morbus Paget des Erwachsenen ist durch langjährige Erfahrungen belegt [40]. Anhand des aktuellen Wissensstandes scheinen Bisphosphonate in der Mehrzahl aller Osteopathien therapeutisch hilfreich zu sein.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literaturverzeichnis
Alharbi M, Pinto G, Finidori G et al. (2008) Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution. Horm Res 71: 38–44
Auron A, Tal L, Srivastava T, Alon US (2009) Reversal of hypercalcemic acute kidney injury by treatment with intravenous bisphosphonates. Pediatr Nephrol: 24(3): 613–617, Epub 2008 Oct 7
Bachrach, L.K., Ward, L.M. (2009) Clinical Review: Bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 94(2): 400–409
Barros ER, Dias da Silva MR, Kunii IS, Lazaretti-Castro M (2008) Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndrome (OPPG) carrying an LRP5 mutation. J Pediatr Endocrinol Metab 21: 811–818
Batch JA, Couper JJ, Rodda C, Cowell CT, Zacharin M (2003) Use of bisphosphonate therapy for osteoporosis in childhood and adolescence. J Paediatr Child Health 39: 88–92
Body JJ, Bartl R, Burckhardt P et al. (1998) Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 16: 3890–3899
Cassinelli HR, Mautalen CA, Heinrich JJ, Miglietta A, Bergada C (1992) Familial idiopathic hyperphosphatasia (FIH): response to long-term treatment with pamidronate (APD). Bone Miner 19: 175–184
Castillo H, Samson-Fang L (2009) Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol 51:17–29
Cecchini MG, Fleisch H (1990) Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage. J Bone Miner Res 5: 1019–1027
Chong B, Hedge M, Fawkner M et al. (2003) Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone Miner Res 18: 2095–2104
Ciana G, Cuttini M, Bembi B (1997) Short-term effects of pamidronate in patients with Gaucher’s disease and severe skeletal involvement. N Engl J Med 337: 712
Chahine C, Cheung MS, Head TW, Schwartz S, Glorieux FH, Rauch F (2008) Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate. J Pediatr 153: 719–720
Cundy T, Hegde M, Naot D et al. (2002) A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 11: 2119–2127
Demir E, Bereket A, Ozkan B, Topcu M (2000) Effect of alendronate treatment on the clinical picture and bone turnover markers in chronic idiopathic hyperphosphatasia. J Pediatr Endocrinol Metab 13 217–221
Evequoz V, Trechsel U, Fleisch H (1985) Effect of bisphosphonates on production of interleukin 1-like activity by macrophages and its effect on rabbit chondrocytes. Bone 6: 439–444
Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, Warman ML (2003) Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 111: 573–578
Fleisch H (1989) Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. Recent Results Cancer Res 116: 1–28
Fleisch H (1991) Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42: 919–944
Fleisch H (1997) Mechanisms of action of the bisphosphonates. Medicina (B Aires) 57, Suppl 1: 65–75
Fleisch H (2001) Zoledronic acid: an evolving role in the treatment of cancer patients with bone disease. Semin Oncol 28: 45–47
Fleisch H (2002) Development of bisphosphonates. Breast Cancer Res 4: 30–34
Fujiwara I, Ogawa E, Igarashi Y, Ohba M, Asanuma A (1998) Intravenous pamidronate treatment in osteogenesis imperfecta. Eur J Pediatr 157: 261–262
Glorieux FH (2001) The use of bisphosphonates in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab: 14, Suppl 6: 1491–1495
Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339: 947–952
Gong L, Hoshi K, Ejiri S, Nakajima T, Shingaki S, Ozawa H (2003) Bisphosphonate incadronate inhibits maturation of ectopic bone induced by recombinant human bone morphogenetic protein 2. J Bone Miner Metab 21: 5–11
Levy S, Fayez I, Taguchi N et al. (2009) Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44(3): 428–430
Marini JC (2003) Do bisphosphonates make children’s bones better or brittle? N Engl J Med 349: 423–426
Montpetit K, Plotkin H, Rauch F, Bilodeau N, Cloutier S, Rabzel M, Glorieux FH (2003) Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics 111: 601–603
Phillipi CA, Remmington T, Steiner RD (2008) Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 4, CD005088
Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH (2000) Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 85: 1846–1850
Rauch F, Glorieux FH (2000) Bisphosphonate in der Pädiatrie. Monschr Kdheilkd 148: 334–341
Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH (2003) Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 88: 986–992
Rauch F, Travers R, Plotkin H, Glorieux FH (2002) The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 110: 1293–1299
Robinson C, Baker N, Noble J et al. (2002) The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment. J Inherit Metab Dis 25: 681–693
Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97: 2692–2696
Roth AJ, Abendroth K, Seidel J, Neubert H, Venbrocks R (1996) Management of primary idiopathic hyperphosphatasemia with calcitonin: a case report. Int Orthop 20: 58–60
Samuel R, Katz K, Papapoulos SE, Yosipovitch Z, Zaizov R, Liberman UA (1994) Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher’s disease. Pediatrics 94: 385–389
Schoenau E, Rauch F (2002) Fibrous dysplasia. Horm Res 57, Suppl2: 79–82
Seidel J, Abendroth K, Müller A, Kauf E (1998) Hyperostosis corticalis deformans juvenilis/HCDJ-Ergebnisse nach 2,5 jähriger Pamidronat-Therapie. Osteologie 7 (Suppl 1): 69
Singer FR, Clemens TL, Eusebio RA, Bekker PJ (1998) Risedronate, a highly effective oral agent in the treatment of patients with severe Pagets disease. J Clin Endocrinol Metab 83: 1906–1910
Singer F, Siris E, Shane E, Dempster D, Lindsay R, Parisien M (1994) Hereditary hyperphosphatasia: 20 year follow-up and response to disodium etidronate. J Bone Miner Res 9: 733–738
Singer FR, Minoofar PN (1995) Bisphosphonates in the treatment of disorders of mineral metabolism. Adv Endocrinol Metab 6 259–288
Srivastava T, Alon US (2003) The role of bisphosphonates in diseases of childhood. Eur J Pediatr 162: 735–751
Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, Hofbauer LC (2002) Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291: 680–686
Vitte C, Fleisch H, Guenther HL (1996) Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137: 2324–2333
Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349: 457–463
Zeitlin L, Rauch F, Plotkin H, Glorieux FH (2003) Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 111: 1030–1036
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Seidel, J. (2010). Einsatz von Bisphosphonaten zur Behandlung von primären und sekundären Osteopathien im Kindes- und Jugendalter. In: Fortbildung Osteologie. Fortbildung Osteologie, vol 3. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-05385-6_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-05385-6_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-05384-9
Online ISBN: 978-3-642-05385-6
eBook Packages: Medicine (German Language)